Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3823898 | 0.92 | TSHR (0.71) | TSHRALDH1A1CYP1A2CYP2C9PTK2B | |
| SCHEMBL3828103 | 0.90 | TSHR (0.65) | TSHRALDH1A1CYP1A2CYP2C9PTK2B | |
| SCHEMBL3824482 | 0.89 | PDE4A (0.59) | TSHRALDH1A1CYP1A2CYP2C9PTK2B | |
| SCHEMBL15106441 | 0.88 | TSHR (0.54) | TSHRALDH1A1PTK2BMEN1KMT2A | |
| SCHEMBL3821434 | 0.88 | TSHR (0.59) | TSHRALDH1A1PTK2BMEN1KMT2A | |
| SCHEMBL7475492 | 0.85 | TSHR (0.55) | TSHRALDH1A1PTK2BMEN1KMT2A | |
| SCHEMBL875834 | 0.85 | PDE4A (0.54) | TSHRALDH1A1PTK2BMEN1KMT2A | |
| SCHEMBL14363850 | 0.84 | KDM4E (0.60) | ALDH1A1MEN1KMT2APDE4APDE4B | |
| SCHEMBL26079023 | 0.84 | MEN1 (0.70) | MEN1KMT2AHDAC6PDE4APDE4B | |
| SCHEMBL7480983 | 0.83 | TSHR (0.52) | TSHRPTK2BMEN1KMT2AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338674-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2021-11-04 | — | — | US | disclosed |
| US-9326984-B2 | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors | ACHE LABORATORIOS FARMACEUTICOS S.A. (BR) | 2016-05-03 | — | — | US | disclosed |
| US-20160008360-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHE LAB FARMACEUTICOS SA (BR) | 2016-01-14 | — | — | US | disclosed |
| US-9169218-B2 | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors | ACHE LABORATORIOS FARMACEUTICOS S.A. (BR) | 2015-10-27 | — | — | US | disclosed |
| EP-2619187-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ LABORATÓRIOS FARMAC UTICOS S A (BR) | 2015-03-04 | — | — | EP | disclosed |
| US-20140336199-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHE LABORATORIOS FARMACEUTICOS S.A., ATC Trustees Abbot Building, 2nd FLoor, Road Town (BR) | 2014-11-13 | — | — | US | disclosed |
| US-20140303179-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHÉ INTERNATIONAL (BVI) LTD. (VG) | 2014-10-09 | — | — | US | disclosed |
| US-8735578-B2 | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2014-05-27 | — | — | US | disclosed |
| EP-2619187-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | Aché Laboratórios Farmacêuticos S.A. (BR) | 2013-07-31 | — | — | EP | disclosed |
| US-20130184286-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ INTERNATIONAL (BVI) LTD. (VG) | 2013-07-18 | — | — | US | disclosed |
| WO-2012037634-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2012-03-29 | — | — | WO | disclosed |
| EP-1793828-A4 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | REDDYS LAB LTD DR (IN) | 2009-09-02 | — | — | EP | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| EP-1793828-A2 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | Dr. Reddy's Laboratories Ltd. (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006029075-A2 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338674-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | HTR2A, HTR5A, HTR2C | TSHR 465/4885ALDH1A1 585/4885CYP1A2 219/4885 |
| US-20160008360-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | HTR2A, HTR5A, HTR2C | TSHR 471/4885ALDH1A1 590/4885CYP1A2 228/4885 |
| US-20140303179-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | HTR5A, HTR2A, HTR1A | TSHR 481/4885ALDH1A1 430/4885CYP1A2 120/4885 |
| US-20140336199-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | HTR5A, HTR2A, HTR2C | TSHR 482/4885ALDH1A1 458/4885CYP1A2 141/4885 |
| US-20130184286-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | HTR5A, HTR2A, HTR2C | TSHR 481/4885ALDH1A1 408/4885CYP1A2 122/4885 |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | PPARA, PPARD, PPARG | TSHR 26/4885ALDH1A1 1248/4885CYP1A2 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.